The Rise of BioNTech’s Ambitions Amidst Revenue Challenges: Bold Moves in Cancer Research
BioNTech is experiencing a financial transition as it shifts focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies. The company reported reduced earnings, with profits per share at €1.08 in…